Clinical Trials Browser

Phase 3 × Urologic Neoplasms × avelumab × Clear all

NCT02603432 2024-03-27

JAVELIN Bladder 100

Phase 3 Completed

700 enrolled 35 charts 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms